<code id='B389AF7680'></code><style id='B389AF7680'></style>
    • <acronym id='B389AF7680'></acronym>
      <center id='B389AF7680'><center id='B389AF7680'><tfoot id='B389AF7680'></tfoot></center><abbr id='B389AF7680'><dir id='B389AF7680'><tfoot id='B389AF7680'></tfoot><noframes id='B389AF7680'>

    • <optgroup id='B389AF7680'><strike id='B389AF7680'><sup id='B389AF7680'></sup></strike><code id='B389AF7680'></code></optgroup>
        1. <b id='B389AF7680'><label id='B389AF7680'><select id='B389AF7680'><dt id='B389AF7680'><span id='B389AF7680'></span></dt></select></label></b><u id='B389AF7680'></u>
          <i id='B389AF7680'><strike id='B389AF7680'><tt id='B389AF7680'><pre id='B389AF7680'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:hotspot    Page View:42
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In